US 12,065,491 B2
Anti-TREM1 antibodies and related methods
Christopher Chan, Pacifica, CA (US); Aritra Pal, San Carlos, CA (US); Venkataraman Sriram, Berkeley, CA (US); Leonard G. Presta, San Francisco, CA (US); Tiep Tu Le, Kensington, CA (US); and Linda Liang, Mountain View, CA (US)
Assigned to Pionyr Immunotherapeutics, Inc., South San Francisco, CA (US)
Filed by Pionyr Immunotherapeutics, Inc., South San Francisco, CA (US)
Filed on Oct. 8, 2020, as Appl. No. 17/066,401.
Application 17/066,401 is a division of application No. 16/852,294, filed on Apr. 17, 2020, granted, now 10,836,828.
Application 16/852,294 is a continuation of application No. PCT/US2020/016949, filed on Feb. 6, 2020.
Claims priority of provisional application 62/889,994, filed on Aug. 21, 2019.
Claims priority of provisional application 62/802,161, filed on Feb. 6, 2019.
Prior Publication US 2021/0101983 A1, Apr. 8, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/585 (2013.01); A61K 45/06 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)] 21 Claims
 
1. A method of increasing an immune response in a subject comprising administering to the subject an isolated antibody that binds to TREM1 (SEQ ID NO: 1) comprising a variable heavy chain (VH) sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and a variable light chain (VL) sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, wherein:
a CDR-H1 comprises the sequence set forth in SEQ ID NO: 23,
b CDR-H2 comprises the sequence set forth in SEQ ID NO: 24,
c CDR-H3 comprises the sequence set forth in SEQ ID NO: 29, wherein X is glutamine (Q), leucine (L), isoleucine (I), or glutamic acid (E),
d CDR-L1 comprises the sequence set forth in SEQ ID NO: 26,
e CDR-L2 comprises the sequence set forth in SEQ ID NO: 27, and
f CDR-L3 comprises the sequence set forth in SEQ ID NO: 28.